Lv7
4510 积分 2022-05-20 加入
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects
1天前
已完结
The expanding landscape of GLP-1 medicines
4天前
已完结
Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology
4天前
已完结
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial
16天前
已关闭
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
2个月前
已完结
Phase I/II study of DZD6008, a 4 th -generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC
4个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
5个月前
已完结
Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer
5个月前
已完结
Efficacy and Safety of Third-Generation EGFR-TKIs Combined with Radiotherapy for Advanced NSCLC with Typical EGFR Mutations: A Retrospective Study
5个月前
已完结
皖公网安备34019202002308
